Short interest for Catalent gives investors a sense of the degree to which investors are betting on the decline of Catalent's stock. Short interest data is updated every two weeks.

Catalent Stock (NYSE:CTLT), Short Interest Report

Catalent

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Wegovy

Trading Ideas

CTLT

BMO&#39;s coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled by strong pipelines and promising trial results.

Novo Nordisk&#39;s Dominance In Obesity &amp; Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating

Ozempic maker Novo Nordisk

Biotech

Large Cap

News

Health Care

Markets

Movers

General

&#34;Novo Nordisk&#39;s optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late 2024, results due early 2026.

Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug

mounjaro-medication-for-weight-loss

Eli Lilly&#39;s strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising demand.

Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk

Catalent Inc

BMO Capital Markets&nbsp;initiated coverage on Danish drug maker&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.&nbsp;
The analyst writes that an in-depth analysis of the growing obesity and adjacent metabolic disease market suggests&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk will remain the two entrenched players in this duopoly.&nbsp;
While other players are just entering the obesity landscape, Novo has been established as a leader since Wegovy&#8217;s approval in 2021 (and Saxenda&#8217;s approval in 2014).&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38222006/novo-nordiskeli-lillys-weight-loss-drugs-does-not-cause-suicidal-behaviors-after-fda-european-med" rel="noreferrer noopener">Novo Nordisk/Eli Lilly&#8217;s Weight Loss Drugs Does Not Cause Suicidal Behaviors &#8211; After FDA, European Medicines Agency Says</a>.
Novo Nordisk&#8217;s decision to double down in obesity assets by developing therapeutics like CagriSema, GLP-1/GIPR agonists, and the new INV-202 has strengthened its pipeline in a market expected to grow to over $130 billion.
In the near term, BMO looks to Phase 3 REDEFINE trial results for CagriSema in obesity and Phase 3 STRIDE and SOUL results for semaglutide in Peripheral arterial disease (PAD) and type-2 diabetes (T2D) with chronic kidney disease (CKD)/ cardiovascular disease (CVD), respectively, to push shares higher.&nbsp;
Trials in secondary indications of obesity/T2D are expected to expand revenue and provide alternate paths to Medicare access.&nbsp;
BMO is initiating with an Outperform rating and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/NVO/analyst-ratings" rel="noreferrer noopener">price target of $163</a>.
Novo&#8217;s growing strength is fueled by various factors, including robust manufacturing, clinical and patient data, diverse pipelines, and enhanced access support, reinforcing the optimistic outlook on Novo Nordisk.&nbsp;
The company, along with Eli Lilly, dominates the market for incretin therapies, with demand rising steadily, especially after the approval of Wegovy.&nbsp;
Capacity limitations in the market, expected to persist until at least 2026, benefit both Novo and Lilly due to their substantial manufacturing capabilities, further bolstered by&nbsp;Catalent Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>).&nbsp;
These constraints fortify Novo Nordisk&#8217;s competitive position, potentially impeding competitors even if they offer superior efficacy or tolerability.
Price Action: NVO shares are down 0.36% at $124.95 on the last check Friday.
Image Via Shutterstock

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating

In the preceding three months, 6 analysts have released ratings for Catalent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Catalent and provided 12-month price targets. The average target is $60.75, accompanied by a high estimate of $63.50 and a low estimate of $47.00. This upward trend is evident, with the current average reflecting a 13.19% increase from the previous average price target of $53.67.
<img src="https://www.benzinga.com/files/images/story/2024/1712242864_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Catalent among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$63.50</td>
<td>-</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$63.50</td>
<td>-</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$63.50</td>
<td>-</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$63.50</td>
<td>$58.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.50</td>
<td>$58.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Catalent. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Catalent compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Catalent's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Catalent analyst ratings.</a>
<h2>Get to Know Catalent Better</h2>
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
<h3>Financial Insights: Catalent</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Catalent's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -10.88%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Catalent's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -20.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Catalent's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.47%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Catalent's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.06%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Catalent's debt-to-equity ratio surpasses industry norms, standing at 1.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

Stephens &amp; Co. analyst Jacob Johnson reiterates Catalent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) with a Equal-Weight and maintains $63.5 price target.

Price Target

Reiteration

Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target

<a href="https://www.businesswire.com/news/home/20240402320363/en/" title="https://www.businesswire.com/news/home/20240402320363/en/">https://www.businesswire.com/news/home/20240402320363/en/</a>

Contracts

Invenra To Collaborate With Catalent To Co-Discover Novel Bispecific ADCs

Novo Nordisk A/S&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) head of development,&nbsp;Martin Holst Lange, expressed strong confidence in the drugmaker&#8217;s ability to launch the pill version of its experimental weight loss drug, amycretin,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37515493/novo-nordisks-semaglutides-multi-beneficial-effects-weight-loss-improved-metabolic-markers-liver-" rel="noreferrer noopener">within this decade</a>.&nbsp;
The optimism follows the announcement of robust early trial data.
&nbsp;The company said early trial data for its experimental obesity drug amycretin showed a higher weight loss than its&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37531875/novo-nordisks-stock-hits-52-week-high-after-highly-sought-after-obesity-drug-trial-data" rel="noreferrer noopener">Wegovy (semaglutide) treatment</a>.
In the Phase 1 trial, oral amycretin showed that participants lost 13.1% of their weight after 12 weeks. That compares to a weight loss of 5.9% after 12 weeks in a trial for Wegovy.
Reuters notes that over 80% of participants remained on amycretin after the trial period, indicating a high retention rate and suggesting the drug&#8217;s safety and tolerability.
Novo Nordisk will begin a Phase 2 trial of its experimental drug amycretin during later 2024, with results due in early 2026.
Novo Nordisk, traditionally recognized for its insulin production, has seen a significant shift in investor perception since the success of Wegovy.&nbsp;
The company anticipates that the newly developed obesity drugs, cagrisema and amycretin, will result in more significant weight loss than the widely used Wegovy.&nbsp;
Moreover, these drugs are expected to offer cardiovascular advantages similar to those of Wegovy. The goal is to introduce these drugs to the market before the patent expiration of semaglutide, the active pharmaceutical ingredient in Wegovy.&nbsp;
The development plan aims to finalize both cagrisema and amycretin for obesity and diabetes within the next two years, well in advance of semaglutide&#8217;s patent expiry.
The company&#8217;s shares have tripled since the U.S. launch of Wegovy in June 2021. CEO&nbsp;Lars Fruergaard Jorgensen&nbsp;anticipates an increased proportion of U.S. patients continuing the weekly injection for over a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37068324/novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-w" rel="noreferrer noopener">year as supply constraints ease</a>.&nbsp;
Jorgensen also expects a growing adoption of obesity drugs as prices decrease over time, balancing with the introduction of new medicine generations that may justify higher prices in specific segments.
Addressing potential regulatory scrutiny, head of business development&nbsp;David Moore&nbsp;acknowledged the uncertainty regarding the U.S. regulatory review of Novo&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36931734/ozempic-maker-strikes-11b-deal-with-catalent-as-it-rushes-to-meet-massive-weight-loss-drug-demand" rel="noreferrer noopener">acquisition of three factories</a>&nbsp;from&nbsp;Catalent Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>).&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/02/37237352/weight-loss-drugs-vs-conagra-foods-company-optimistic-amid-shifting-consumer-demands-influenced-by" rel="noreferrer noopener">Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing</a>.
Price Action: NVO shares are down 1.99% at $133.22 on the last check Friday.
Photo via Shutterstock

Novo Nordisk CFO Says If Catalent Deal Does Not Close, More Capex Will Be Needed To Build Fill-Finish Capacity Internally

Novo Nordisk CFO Says If Catalent Deal Does Not Close, Novo Will Also Do More Deals With Contract Drugmakers; Exec Says There Is Still Opportunity To Acquire Companies To Add To Its Obesity Pipeline

Eli Lilly&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound (tirzepatide), as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and &#8220;finishing&#8221; of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35142181/weight-loss-drug-boom-has-another-ripple-effect-rapid-growth-expected-in-fill-finish-market" rel="noreferrer noopener">its injector pens</a>.
BSP Pharmaceuticals and National Resilience are among the specialized contract manufacturers capitalizing on the obesity drug boom.&nbsp;
The global contract development and manufacturing market is poised to grow from $72 billion to $90 billion in the next two years, highlighting the urgency for increased fill-finish capacity.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37430399/eli-lillys-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-increti" rel="noreferrer noopener">Eli Lilly&#8217;s Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets</a>.
Eli Lilly and&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) have invested billions to address bottlenecks in active ingredient production and fill-finish as the companies grapple with a shortage of the most sought-after&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37068324/novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-w" rel="noreferrer noopener">drugs for diabetes and weight loss</a>.
Despite Novo Nordisk&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36931734/ozempic-maker-strikes-11b-deal-with-catalent-as-it-rushes-to-meet-massive-weight-loss-drug-demand" rel="noreferrer noopener">recent acquisition</a>&nbsp;of three &#8220;fill-finish&#8221; plants from&nbsp;Catalent Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), the company will not be able to scale up production until 2026, the Financial Times noted.
National Resilience, a recipient of a $410 million loan from the U.S. defense department, aims to fill Zepbound injector pens at its Cincinnati plant, with a total capacity of 200 million doses by 2025.&nbsp;
Meanwhile, the Financial Times&nbsp;<a target="_blank" href="https://www.ft.com/content/f7bc9af9-4643-481a-94e8-ac87547123a8" rel="noreferrer noopener">noted</a>&nbsp;that BSP is gearing up to produce 61 million injectable doses of non-cancer drugs by the end of next year.
As Eli Lilly accelerates production through external collaborations, challenges in the fill-finish stage persist due to close-to-full production capacities.&nbsp;
Citing industry experts, the Financial Times highlights that while oral weight-loss pills are under development by major players, supply constraints may persist for several years.&nbsp;
The global contract drug manufacturer market, though expanding, may not provide an immediate solution to the escalating demand for obesity drugs, leaving Eli Lilly and Novo Nordisk in a race against time.
Price Action:&nbsp;LLY shares are up 1.19% at $786.85 during the premarket session on the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Company

The U.S. stock market continues its unchallenged bull run, with Wall Street notching yet another week of record-breaking highs for the S&amp;P 500 <a href="https://www.benzinga.com/news/earnings/24/03/37427925/s-p-500-nasdaq-100-hit-record-highs-as-dollar-treasury-yields-weaken-chipmakers-shine-nycb-sinks-wh">and Nasdaq 100 indices.</a>
This ongoing surge demonstrates the remarkable strength of the bullish sentiment, with stocks marking their 16th positive week out of the last 18. Since late October, this rally has propelled the S&amp;P 500 index by 25% and the Nasdaq 100 by 30%.
The momentum on Wall Street has also catapulted the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – the world&#8217;s largest exchange traded fund – to a historic milestone, surpassing $500 billion in assets under management for the first time ever.
Trailing behind the SPY are BlackRock&#8217;s iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) with $442 billion, and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) with $413 billion under management. 
Other notable milestones were achieved among S&amp;P 500 components during Friday&#8217;s session. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reached a market capitalization exceeding $2 trillion, Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) surpassed $700 billion and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) overtook Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) to become the eighth-most valuable company.
<h2 class="wp-block-heading">Chart: SPY Is First ETF To Reach $500 Billion In AUM</h2>
<img decoding="async" src="https://www.benzinga.com/files/images/story/2024/1709327108_0.png" alt="" />
<h2 class="wp-block-heading">Top-Performing S&amp;P 500 Stocks Friday</h2>
The following are the five top-performing stocks within the S&amp;P 500 on Friday: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Stock Name</th>
<th>Sector</th>
<th>Price</th>
<th>1-Day Return %</th>
</tr>
</thead>
<tbody>
<tr>
<td>NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>)</td>
<td>Information Technology</td>
<td>106.93</td>
<td>19.98%</td>
</tr>
<tr>
<td>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>)</td>
<td>Health Care</td>
<td>102.07</td>
<td>9.05</td>
</tr>
<tr>
<td>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>Information Technology</td>
<td>63.99</td>
<td>7.61</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>Information Technology</td>
<td>1,392.56</td>
<td>7.08</td>
</tr>
<tr>
<td>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>Health Care</td>
<td>121.19</td>
<td>5.32</td>
</tr>
</tbody>
</table>
</figure>
<h2 class="wp-block-heading">Top 10 Performing S&amp;P 500 Stocks Year-To-Date</h2>
The top-performing S&amp;P 500 stocks year-to-date are as follows:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>YTD Return</td>
<td>Market Cap</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>65.43%</td>
<td>$2,016B</td>
</tr>
<tr>
<td>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>44.19%</td>
<td>$53.37B</td>
</tr>
<tr>
<td>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>41.97%</td>
<td>$1,281.15B</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>36.55%</td>
<td>$325.24B</td>
</tr>
<tr>
<td>Eli Lilly and Company </td>
<td>33.72%</td>
<td>$701.64B</td>
</tr>
<tr>
<td>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)</td>
<td>31.30%</td>
<td>$167.86B</td>
</tr>
<tr>
<td>Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</td>
<td>29.60%</td>
<td>$174.53B</td>
</tr>
<tr>
<td>Ralph Lauren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)</td>
<td>28.68%</td>
<td>$11.86B</td>
</tr>
<tr>
<td>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)</td>
<td>28.57%</td>
<td>$10.85B</td>
</tr>
<tr>
<td>Catalent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>)</td>
<td>28.18%</td>
<td>$10.34B</td>
</tr>
</tbody>
</table>
</figure>
Read now: <a href="https://www.benzinga.com/general/biotech/24/02/37408271/top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-heres-what-investors-think-wall-street">Top Stocks Not Named Nvidia You Need To Know About In 2024: Here&#8217;s What Investors Think About Them (Wall Street Vs. Reddit)</a>
Photo via Shutterstock.

Equities

Broad U.S. Equity ETFs

Tech

ETFs

AMAT

AVGO

DXCM

JNPR

NTAP

NVDA

TSLA

UBER

Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has undoubtedly emerged as the standout performer among S&amp;P 500 stocks in the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37288423/nvidia-spikes-to-2-trillion-market-cap-as-fomo-drives-traders-into-stock-the-journe">initial two months of 2024</a>.
While the Santa Clara, California-based tech company enjoyed a 60% gain, there&#8217;s a pack of lesser-trumpeted names that have quietly delivered impressive returns in their own right. 
These stocks have significantly <a href="https://www.benzinga.com/money/what-makes-the-stock-market-go-up-and-down">outpaced the broader market</a>.
Within the S&amp;P 500 index, 10 stocks have achieved returns exceeding 25% so far this year. Noteworthy among them are three from the Magnificent Seven subset, showcasing the enduring strength of <a href="https://www.benzinga.com/topic/magnificent-seven">mega-cap tech players.</a>
In contrast, the median S&amp;P 500 stock, tracked by the S&amp;P 500 Equal Weight ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSP#NYSE">RSP</a>), has eked out a modest 3% return, while the market-cap weighted SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has posted a more substantial 7% surge.
<h3 class="wp-block-heading">Top 10 Performing S&amp;P 500 Stocks (As Of Feb. 29, 2024)</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>YTD Return</td>
<td>Market Cap</td>
</tr>
<tr>
<td>NVIDIA Corporation </td>
<td>60.02%</td>
<td>$1,950.35B</td>
</tr>
<tr>
<td>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>43.31%</td>
<td>$53.04B</td>
</tr>
<tr>
<td>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>38.14%</td>
<td>$1,246.58B</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>29.17%</td>
<td>$307.66B</td>
</tr>
<tr>
<td>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>29.03%</td>
<td>$677.07B</td>
</tr>
<tr>
<td>Ralph Lauren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)</td>
<td>28.37%</td>
<td>$11.83B</td>
</tr>
<tr>
<td>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)</td>
<td>28.27%</td>
<td>$10.83B</td>
</tr>
<tr>
<td>Catalent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>)</td>
<td>28.24%</td>
<td>$10.41B</td>
</tr>
<tr>
<td>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)</td>
<td>28.18%</td>
<td>$163.88B</td>
</tr>
<tr>
<td>Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>)</td>
<td>25.12%</td>
<td>$11.96B</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">What Wall Street Thinks&#8230;</h3>
Investors are likely considering whether the top-performing stocks still offer room for further growth, given their already impressive returns.
A reliable measure to gauge this potential is comparing the current stock price with the 1-year median price target projected by Wall Street analysts.
Among the top 10 S&amp;P 500 stocks year-to-date, Uber Technologies stands out with the largest potential upside to its median price target, showing a significant difference of 13.8%. Catalent follows closely behind, boasting a 10% potential upside, while Nvidia still maintains a respectable 7% upside compared to its median price target.
However, it&#8217;s worth noting that there are other stocks within the S&amp;P 500 index showing even more substantial potential upside.
Here&#8217;s a summary of the significant disparities between current market prices and Wall Street analysts&#8217; forecasts within a one-year horizon.
<h4 class="wp-block-heading">Top 10 S&amp;P 500 Stocks By Upside Potential Vs. Wall Street&#8217;s Price Target</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-Year Price Target (Med) vs Current Price</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>54.73%</td>
</tr>
<tr>
<td>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>46.80%</td>
</tr>
<tr>
<td>Caesars Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NYSE">CZR</a>)</td>
<td>45.11%</td>
</tr>
<tr>
<td>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</td>
<td>43.79%</td>
</tr>
<tr>
<td>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</td>
<td>43.12%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>41.12%</td>
</tr>
<tr>
<td>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>)</td>
<td>41.03%</td>
</tr>
<tr>
<td>Carnival Corporation &amp; pIc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)</td>
<td>38.85%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>36.04%</td>
</tr>
<tr>
<td>Baker Hughes Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>)</td>
<td>35.75%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">What Reddit Users Think&#8230;</h3>
A method for gauging social sentiment among U.S. stocks is provided by the VanEck Social Sentiment ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUZZ#NYSE">BUZZ</a>). 
This fund allocates investments to companies that exhibit favorable insights gathered from various online sources, such as social media platforms, news articles, blog posts, and other alternative datasets.
Below, a table highlights the top 10 holdings within the BUZZ ETF, along with their year-to-date performance:
<h3 class="wp-block-heading">Most-Loved Stocks By Social Users</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Weight In Buzz ETF</td>
<td>YTD Return</td>
</tr>
<tr>
<td>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)</td>
<td>4.36%</td>
<td>16.00%</td>
</tr>
<tr>
<td>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)</td>
<td>3.42</td>
<td>61.51</td>
</tr>
<tr>
<td>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>3.37</td>
<td>203.07</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>3.21</td>
<td>60.06</td>
</tr>
<tr>
<td>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)</td>
<td>3.16</td>
<td>-9.55</td>
</tr>
<tr>
<td>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)</td>
<td>3.09</td>
<td>-1.68</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>3.07</td>
<td>-19.05</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>3.00</td>
<td>29.65</td>
</tr>
<tr>
<td>Meta Platforms, Inc.</td>
<td>2.96</td>
<td>38.49</td>
</tr>
<tr>
<td>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2.93</td>
<td>15.23</td>
</tr>
</tbody>
</table>
</figure>
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37402333/exclusive-magnificent-7-takes-center-stage-in-roundhills-expanded-etf-lineup-with-i">EXCLUSIVE: Magnificent 7 Takes Center Stage In Roundhill&#8217;s Expanded ETF Lineup With Inverse And Leveraged Options</a>
Image: Midjourney

Mid Cap

Social Media

Small Cap

AMZN

BIIB

BUZZ

COIN

FSLR

MSTR

PODD

PYPL

Rydex ETF Trust Rydex S&P Equal Weight ETF

SMCI

SOFI

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)

Catalent's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) short percent of float has fallen 33.03% since its last report. The company recently reported that it has 7.45 million shares sold short, which is 5.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Catalent Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709141410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Catalent has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Catalent's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Catalent's peer group average for short interest as a percentage of float is 3.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CTLT) - Analyzing Catalent's Short Interest

The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the <a href="https://www.benzinga.com/topic/weight-loss">Danish company&#8217;s shares 30% higher</a>.
Zealand Pharma&#8217;s survodutide drug showed positive results in 83% of patients in Phase 2 trials being tested for a liver disease caused by excess fat cells called MASH, the company <a href="https://www.zealandpharma.com/media/zealand-news/">announced</a> on Monday.
&#8220;Survodutide has demonstrated efficacy in people with obesity, and statistically significant results in MASH suggest the potential to lead to clinically meaningful benefits across the cardiovascular, renal, and metabolic spectrum,&#8221; the announcement said.
The blockbuster impact of drugs such as Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Eli Lilly And Company&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro, have driven dozens of companies to research and develop rival weight-loss treatments and further announcements of breakthroughs in the fast-developing market are expected in 2024. 
<h2 class="wp-block-heading">Impact Of Weight-Loss Drugs On Q4 Results</h2>
Currently, they are the main two players. Thanks to its Mounjaro and Zepbound treatments, Eli Lilly crushed analysts estimates for fourth-quarter earnings, <a href="https://www.benzinga.com/markets/equities/24/02/36955955/eli-lilly-soars-on-diabetes-and-obesity-drug-boom-projects-20-revenue-increase-in-2024">reported</a> earlier this month, with a 19% increase in earnings per share to $2.49, beating Street expectations of $2.22.
Upgrades soon followed with analysts from Cantor Fitzgerald and Morgan Stanley raising their price targets on the stock.
Novo Nordisk&#8217;s <a href="https://www.benzinga.com/general/biotech/24/01/36865688/with-bumper-33b-sales-novo-nordisk-forecasts-double-digit-2024-earnings-growth-boosts-lower-dose-">results</a> were similarly impressive, with its Wegovy and Ozempic offerings helping fourth-quarter sales to soar 37% to $9.5 billion, compared with expectations of $8.82 billion.
<h2 class="wp-block-heading">Market To Become More Crowded</h2>
Health and medical information research company Stat, <a href="https://www.statnews.com/2023/09/12/obesity-weight-loss-mounjaro-drug-development/">suggests</a> that around 70 weight loss drugs are currently in development to catch the exploding market — including from large and well-established pharma companies such as AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
This suggests the early runners, Novo Nordisk and Eli Lilly, will find the space becoming more crowded in the months to come as many newly-developed treatments receive fast-track drug designations from global regulators.
How can they respond? They can certainly make hay while the sun shines — indeed, Novo recently <a href="https://www.benzinga.com/general/biotech/24/02/36931734/ozempic-maker-strikes-11b-deal-with-catalent-as-it-rushes-to-meet-massive-weight-loss-drug-demand">announced the acquisition</a> of Catalent Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), a New Jersey-based manufacturing facility, so that it can scale up production of Wegovy and Ozempic within their biggest market.
Meanwhile, Eli Lilly has turned its focus to the marketing side of its blockbuster treatments, announcing in January the launch of a new digital health-care platform, LillyDirect, that will offer drugs directly to consumers who have been prescribed the medications. 
Shares in both Novo and Eli Lilly have outperformed broader measures of pharmaceutical stocks. Novo is up 19% so far this year, while Eli Lilly has gained 33%.
The iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>), an exchange traded fund that tracks U.S. pharma companies, is up 12.5% in 2024.
Now Read: <a href="https://www.benzinga.com/markets/equities/24/02/37312557/hallelujah-for-shale-why-warren-buffett-likes-american-oil-companies">&#8216;Hallelujah&#8217; For Shale: Why Warren Buffett Likes American Oil Companies</a>
Photo: Shutterstock

Earnings

Sector ETFs

iShares Dow Jones US Pharmaceuticals Index Fund

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors

Across the recent three months, 5 analysts have shared their insights on Catalent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high estimate of $63.50, and a low estimate of $47.00. Observing a 12.17% increase, the current average has risen from the previous average price target of $53.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1708455643_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Catalent is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$63.50</td>
<td>-</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$63.50</td>
<td>-</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$63.50</td>
<td>$58.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.50</td>
<td>$58.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Catalent. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Catalent compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Catalent's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Catalent's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Catalent analyst ratings.</a>
<h2>About Catalent</h2>
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
<h3>Key Indicators: Catalent's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Catalent faced challenges, resulting in a decline of approximately -10.88% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Catalent's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -20.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Catalent's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.47%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Catalent's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.06%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Catalent's debt-to-equity ratio stands notably higher than the industry average, reaching 1.36. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 5 Analyst Recommendations For Catalent

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) with a Sector Perform and maintains $63.5 price target.

RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target

Management

Catalent Says During 3 Months Ended Dec 31, 2023, Extends Restructuring Efforts To Reduce Costs, Headcount In Biologics & Pharma, Consumer Health Segments; Reduced Headcount By About 300 Employees, Incurred Cumulative Employee-Related Charges Of ~$12M

Catalent Says Upon Termination Of Merger With Novo Nordisk's Parent Company, Catalent Could Be Required To Pay A Termination Fee Of About $345M

As the S&amp;P 500 index continues to hover near the 5,000-point threshold, not far from its all-time highs, the remarkable surge of over 20% since late October levels created a stark divide with many corporations failing to <a href="https://www.benzinga.com/markets">join the market rally. </a>
As of mid-February, nearly half of S&amp;P 500 stocks were trading below the 50-day moving average, which represents a widely recognized technical indicator employed by traders for evaluating the short to medium-term direction of a stock&#8217;s price movement.
This observation suggests a substantial portion of the index&#8217;s components remains ensnared by bearish sentiment, highlighting a poor market breadth.
<h2 class="wp-block-heading">Chart: Only 51% Of S&amp;P 500 Stocks Is Trading Above 50-Day Moving Average</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30-1024x495.png" alt="" class="wp-image-216010" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/02/14114915/image-30.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In total, there are 232 S&amp;P 500 stocks currently trading below their 50-day moving averages, among which 202 have a market capitalization of less than $100 billion. The remaining 30 stocks belong to the echelons of mega-cap companies, although they constitute just one-third of that exclusive group.
The contrast becomes even more pronounced when considering that only five out of the top 30 companies in the index are trading below their 50-day moving average. This suggests the elite tier of the S&amp;P 500 largely remained well shielded from bearish pressures. 
<h2 class="wp-block-heading">Top 10 Cheapest S&amp;P 500 Companies, According To 50-Day Moving Average </h2>
Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), and MarketAxess Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) are the three companies that trade the most &#8220;at a discount&#8221; relative to this technical indicator with distances of 20%, 19%, and 17%, respectively, off the 50-day average. None of these three corporations have a market capitalization in excess of $50 billion.
A significant surprise comes in fourth place, as Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is positioned there, about 16% off its 50-day average. 
With a market capitalization of almost $590 billion, Tesla is one of the mega-cap outliers in the group of S&amp;P 500 companies that trade below the 50-day average. Within this group, there is Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), now 11% away from its moving average.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td> Price vs. 50D Average</td>
<td>Price Chg. % (YTD)</td>
</tr>
<tr>
<td>Charter Communications, Inc.</td>
<td>-20.07%</td>
<td>-25.59%</td>
</tr>
<tr>
<td>Archer-Daniels-Midland Company</td>
<td>-19.38%</td>
<td>-26.96%</td>
</tr>
<tr>
<td>MarketAxess Holdings Inc.</td>
<td>-16.44%</td>
<td>-25.02%</td>
</tr>
<tr>
<td>Tesla, Inc.</td>
<td>-16.30%</td>
<td>-25.12%</td>
</tr>
<tr>
<td>Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>)</td>
<td>-16.07%</td>
<td>-20.74%</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-15.81%</td>
<td>-20.97%</td>
</tr>
<tr>
<td>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>-15.17%</td>
<td>-23.05%</td>
</tr>
<tr>
<td>Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>)</td>
<td>-12.55%</td>
<td>-15.45%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>-12.51%</td>
<td>-17.42%</td>
</tr>
<tr>
<td>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</td>
<td>-12.47%</td>
<td>-16.66%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">Top 10 Richest S&amp;P 500 Companies, According To 50-Day Moving Average</h1>
Inverting the focus to stocks that have largely exceeded the 50-day moving average&#8217;s support, NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Ely Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) lead the ranking, with 32%, 25%, and 21%, respectively, price premiums compared to the technical indicator. 
Uber Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>) and Ralph Lauren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) follow closely after with a 20% premium.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td> Price vs. 50D Average</td>
<td>Price Chg. % (YTD)</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>32.40%</td>
<td>49.35%</td>
</tr>
<tr>
<td>Meta Platforms, Inc.</td>
<td>24.70%</td>
<td>33.16%</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>21.09%</td>
<td>30.65%</td>
</tr>
<tr>
<td>Uber Technologies, Inc.</td>
<td>20.59%</td>
<td>25.00%</td>
</tr>
<tr>
<td>Ralph Lauren Corporation</td>
<td>20.26%</td>
<td>20.76%</td>
</tr>
<tr>
<td>Catalent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>)</td>
<td>18.79%</td>
<td>25.93%</td>
</tr>
<tr>
<td>Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</td>
<td>18.05%</td>
<td>16.14%</td>
</tr>
<tr>
<td>Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</td>
<td>17.51%</td>
<td>23.15%</td>
</tr>
<tr>
<td>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</td>
<td>16.82%</td>
<td>18.02%</td>
</tr>
<tr>
<td>Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</td>
<td>16.02%</td>
<td>26.34%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37119249/nvidias-rally-at-risk-short-seller-jim-chanos-says-thats-bad-if-true-after-analyst-">Nvidia&#8217;s Rally At Risk? Short Seller Jim Chanos Says &#8216;That&#8217;s Bad &#8230; If True&#8217; After Analyst Spots Potential Red Flag</a>

Technicals

CHTR

LRCX

MKTX

MPWR

PANW

PEAK

Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?

The unprecedented demand for weight loss drugs, including&nbsp;Novo Nordisk A/S&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and&nbsp;Eli Lilly And Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound, has created a supply crunch, leaving patients struggling to access&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36954087/investors-cheer-highly-awaited-eli-lilly-earnings-q4-performance-surpass-expectations-thanks-to-s" rel="noreferrer noopener">these injectable treatments</a>.&nbsp;
With obesity medications expected to reach 15 million U.S. adults by 2030, the weight loss drug market could potentially be valued at $100 billion by the end of the decade.
Novo Nordisk and Eli Lilly are actively working to increase supply to meet the demand spikes. Both companies have recently provided updates on their positive supply developments, assuring investors and patients.
Novo Nordisk revealed significant progress in increasing the supply of its lower-dose versions of Wegovy in January, doubling the availability compared to previous months.&nbsp;
&#8220;I think it&#8217;s going to take a few years for it to resolve itself,&#8221; Cantor Fitzgerald analyst Louise Chen&nbsp;<a target="_blank" href="https://www.cnbc.com/2024/02/10/weight-loss-drugs-novo-nordisk-eli-lilly-are-tackling-supply-issues.html" rel="noreferrer noopener">told</a>&nbsp;CNBC of the supply issues. &#8220;But I think both companies will slowly start to meet the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36865688/with-bumper-33b-sales-novo-nordisk-forecasts-double-digit-2024-earnings-growth-boosts-lower-dose-" rel="noreferrer noopener">demand in the market</a>.&#8221;&nbsp;
Last week, Novo Nordisk agreed to acquire three fill-finish sites from Novo Holdings,&nbsp;its largest shareholder, in connection with a transaction where Novo Holdings agreed to acquire&nbsp;Catalent Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>). Novo Nordisk will acquire the three manufacturing sites for an&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/36986742/catalents-bloomington-plant-making-novo-nordisks-obesity-drug-faces-fda-scrutiny-regarding-drug-manu" rel="noreferrer noopener">upfront payment of $11 billion</a>.&nbsp;
The three manufacturing sites specialize in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana, US).&nbsp;
Eli Lilly, facing challenges with the limited availability of certain doses of its diabetes drug Mounjaro, has doubled its production capacity for incretin drugs.&nbsp;
The company plans to expand production further in the second half of the year, ensuring at least a 1.5-fold increase compared to the second half of 2023.
Limited quantities of Eli Lilly&#8217;s diabetes drug Mounjaro (tirzepatide) in higher doses (10 mg, 12.5 mg, and 15 mg) will be accessible until early March 2024,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36936648/whats-going-on-with-eli-lilly-stock-today" rel="noreferrer noopener">per the FDA&#8217;s website</a>.&nbsp;
In November, Eli Lilly said it intends to construct a production plant in western Germany with an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35833897/pharmaceutical-giant-eli-lilly-plans-expansion-in-germany-eyes-diabetes-drug-production-report" rel="noreferrer noopener">estimated investment of €2 billion</a>.
Novo Nordisk and Eli Lilly are exploring alternative forms of weight loss drugs to alleviate supply constraints.&nbsp;
Eli Lilly, in particular, aims to launch Mounjaro in a delivery device called KwikPen outside the U.S., leveraging existing manufacturing&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36790349/eli-lillys-famed-obesity-and-diabetes-drug-mounjaro-comes-to-uk-patients-wins-regulatory-clearanc" rel="noreferrer noopener">resources to meet demand</a>.&nbsp;
Additionally, the development of oral drugs may provide a more accessible and cost-effective solution to meet the soaring market demand.
Price Action: LLY shares are up 0.01% at $740.20, NVO shares are down 0.79% at $120.24 during the premarket session on the last check Monday.
Image Via Shutterstock

Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs

Catalent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.02) by 1100 percent. This is a 135.82 percent decrease over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $1.03 billion which beat the analyst consensus estimate of $1.01 billion by 2.18 percent. This is a 10.18 percent decrease over sales of $1.15 billion the same period last year.

Catalent Q2 Adjusted EPS $(0.24) May Not Be Comparable To $(0.02) Estimate, Sales $1.03B Beat $1.01B Estimate

The resilient U.S. stock market is on track to close the week on a positive note as futures pointed to a modestly higher open on Friday, with the small-cap space potentially leading the upside. Earnings reactions&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/02/37019165/pinterest-q4-earnings-revenue-miss-eps-beat-monthly-active-users-up-11-and-more" rel="noreferrer noopener">have largely been negative</a>, and oil has reversed course. The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory. Seasonal factor revisions to the Labor Department&#8217;s consumer price inflation estimates and a speech by the Federal Reserve could also guide the trading direction for the session.
Cues From Thursday's Trading:
The ongoing earnings growth momentum helped allay trader concerns about a potential pullback from record high levels and the rate worries triggered by the jobless claims data, which reinforced the strength of the labor market and, in turn, the economy. The extended rally in crude oil propped up energy stocks.
The major averages opened Thursday&#8217;s session higher and lost ground immediately after. The Nasdaq Composite recovered and stayed above the unchanged line throughout the remainder of the session. The S&amp;P 500 Index and the Dow Industrials, the record breakers, traded mostly lower before making a comeback in late trading. The latter two averages raced to fresh record closes, with the S&amp;P 500 Index breaking above the 5,000 psychological barrier for the first time ever.
Among S&amp;P sector classes, energy stocks gained notably, while real estate and communication services stocks also found modest buying. On the other hand, financial, material, utility, and healthcare ended lower.
 US Index Performance On Thursday
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.95%</td>
<td>15,756.64</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.06%</td>
<td>4,997.91</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.13%</td>
<td>38,726.33</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.17%</td>
<td>1,953.63</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> Analyst Color:</figcaption></figure>
Shrugging off the recent consolidation phase in the market, a fund manager said the momentum continues to be higher. &#8220;Stocks are digesting the recent gains, but the momentum continues higher,&#8221; said Louis Navellier.&nbsp;
He also said traders weren&#8217;t too worried by the rise in bond yields. Despite the significant run-up in interest rates in February, all major indices, except the Russell 2,00 Index, have powered here, he said.
&#8220;The linkage to interest rates appears to be weakening,&#8221; Navellier said.
&#8220;It appears likely that if the S&amp;P can close above 5,000 in the next few days we could see another leg up, though the seasonally weak month of March is looming.&#8221;
Carson Group&#8217;s Ryan Detrick shared historical data to show why the S&amp;P 500&#8217;s break above the 5,000 mark is a harbinger of better times to come. Six months after the S&amp;P 500 hit a major milestone, the returns were higher 100% of the time and the average gain was 8%. A year later, the probability of gain drops to 80% but the average return is 8.6%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s a visual of what happens after major milestones are hit on the S&amp;P 500. <a href="https://t.co/3UOkVkFzMF">pic.twitter.com/3UOkVkFzMF</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1755701030409433157?ref_src=twsrc%5Etfw">February 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Futures Today Futures Performance On Friday</figcaption></figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.36%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.19%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.09%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.58%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://www.benzinga.com/premarket/">In premarket trading</a> on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) moved up 0.21% to $499.38 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) added 0.37% to $434.40, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data.</a>
Upcoming Economic Data:
The Labor Department will release seasonal factor revisions to its consumer price inflation estimates at 8:30 a.m. ET. Given the inflation obsession of the Fed, the revisions could attract attention.
Dallas Fed President Lorie Logan is scheduled to speak at 1:30 a.m. ET.
See Also: <a href="https://www.benzinga.com/money/best-brokers-futures-traders">Best Futures Brokers</a> 
Stocks In Focus:
<ul>
<li>Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) climbed about 27% in premarket trading in reaction to its earnings announcement.</li>
<li>Other stocks reacting to earnings are Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) (down about 9%), Boyd Gaming Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NASDAQ">BYD</a>) (up about 4%), Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) (down over 15%), Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) (down about 2%), Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) (down about 8.50%), and Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) (down about 8.50%).</li>
<li>Catalent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>), and PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) are among the notable companies due to report their earnings ahead of the market opening.</li>
<li>WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) jumped over 15.5% after the company, which was spun off from Kellogg, late last year, declared a dividend.</li>
</ul>
Commodities, Bonds, Other Global Equity Markets:
Crude oil futures edged down 0.10% to $76.14 in early European session on Friday, as the commodity snapped a four-session winning streak. On Thursday, oil spiked over 3%. The benchmark 10-year Treasury note edged down 0.004 percentage points to 4.166% on Thursday.
As a slew of markets in Asia remained closed for the Chinese New Year holiday, the sentiment elsewhere in the region was muted. The major European markets traded mixed in late-morning trading.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37027458/peter-schiff-flags-big-risk-for-stock-markets-record-run-warns-of-false-belief-abou">Peter Schiff Flags &#8216;Big Risk&#8217; For Stock Market&#8217;s Record Run, Warns Of &#8216;False Belief&#8217; About Inflation War</a>

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

AFRM

EXPE

ILMN

PINS

TTWO

US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities

Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities

Wall Street is positive on Catalent Inc (CTLT). On average, analysts give CTLT a Buy rating. The average price target is $60.071, which means analysts expect the stock to increase by 6.74% over the next twelve months.That average ranking earns CTLT an Analyst Rating of 18, which is better than 18% of stocks based on data c

What is Wall Street's Target Price for Catalent Inc (CTLT) Stock Monday?

International Companies Drive Diabesity Innovation

Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalent (CTLT – Research Report), Alvotech (ALVO ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

Top 10 best performing S&P 500 health care stocks of 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catalent (CTLT – Research Report), Vertex Pharmaceut...

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

Laughing Water Capital Q1 2024 Letter

Goldman's debt issuers stocks basket

ALGN

ALKS

ALVO

AMGN

APTV

ARKG

BEIGF

BGNE

CARR

CDMO

FICO

FOXA

GEHC

GRRMY

HALO

HSIC

IMCR

INTC

IVBIY

IVBXF

KLAC

KVUE

LFCR

MKGAF

MKKGY

NCLH

NNAVW

NONOF

NVSEF

NWSA

NXNVW

NXPI

ORCL

STVN

TACT

THRY

TRGP

TRMB

VLTO

VRTX

WUXAY

WUXIF

WXIBF

WXXWY

ZBRA

Legal

Press Releases

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA

Penny Stocks

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Catalent Stock (NYSE:CTLT), Short Interest Report

People Also Watch